162 related articles for article (PubMed ID: 31092094)
1. Uridine diphosphate glucuronosyltransferase 1A1.
Steventon G
Xenobiotica; 2020 Jan; 50(1):64-76. PubMed ID: 31092094
[TBL] [Abstract][Full Text] [Related]
2. UGT genotyping in belinostat dosing.
Goey AK; Figg WD
Pharmacol Res; 2016 Mar; 105():22-7. PubMed ID: 26773202
[TBL] [Abstract][Full Text] [Related]
3. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing.
Gammal RS; Court MH; Haidar CE; Iwuchukwu OF; Gaur AH; Alvarellos M; Guillemette C; Lennox JL; Whirl-Carrillo M; Brummel SS; Ratain MJ; Klein TE; Schackman BR; Caudle KE; Haas DW;
Clin Pharmacol Ther; 2016 Apr; 99(4):363-9. PubMed ID: 26417955
[TBL] [Abstract][Full Text] [Related]
4. Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patients.
Wang LZ; Ramírez J; Yeo W; Chan MY; Thuya WL; Lau JY; Wan SC; Wong AL; Zee YK; Lim R; Lee SC; Ho PC; Lee HS; Chan A; Ansher S; Ratain MJ; Goh BC
PLoS One; 2013; 8(1):e54522. PubMed ID: 23382909
[TBL] [Abstract][Full Text] [Related]
5. Combined use of irinotecan with histone deacetylase inhibitor belinostat could cause severe toxicity by inhibiting SN-38 glucuronidation via UGT1A1.
Wang L; Chan CEL; Wong AL; Wong FC; Lim SW; Chinnathambi A; Alharbi SA; Lee LS; Soo R; Yong WP; Lee SC; Ho PC; Sethi G; Goh BC
Oncotarget; 2017 Jun; 8(25):41572-41581. PubMed ID: 28157715
[TBL] [Abstract][Full Text] [Related]
6. Effects of common genetic variants of human uridine diphosphate glucuronosyltransferase subfamilies on irinotecan glucuronidation.
Tagawa K; Maruo Y; Mimura Y; Ikushiro S
Toxicol Mech Methods; 2023 Mar; 33(3):197-205. PubMed ID: 35930428
[TBL] [Abstract][Full Text] [Related]
7. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism.
Iyer L; Hall D; Das S; Mortell MA; Ramírez J; Kim S; Di Rienzo A; Ratain MJ
Clin Pharmacol Ther; 1999 May; 65(5):576-82. PubMed ID: 10340924
[TBL] [Abstract][Full Text] [Related]
8. In vitro characterization of belinostat glucuronidation: demonstration of both UGT1A1 and UGT2B7 as the main contributing isozymes.
Dong D; Zhang T; Lu D; Liu J; Wu B
Xenobiotica; 2017 Apr; 47(4):277-283. PubMed ID: 27180825
[TBL] [Abstract][Full Text] [Related]
9. Tocilizumab-induced hyperbilirubinemia in Japanese patients with rheumatoid arthritis: its association with UDP glucuronosyltransferase 1A1 gene polymorphisms.
Mori S; Terada K; Ueki Y
Mod Rheumatol; 2012 Aug; 22(4):515-23. PubMed ID: 21993917
[TBL] [Abstract][Full Text] [Related]
10. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes.
Iyer L; King CD; Whitington PF; Green MD; Roy SK; Tephly TR; Coffman BL; Ratain MJ
J Clin Invest; 1998 Feb; 101(4):847-54. PubMed ID: 9466980
[TBL] [Abstract][Full Text] [Related]
11. Effect of the UGT1A1*28 allele on unconjugated hyperbilirubinemia in HIV-positive patients receiving Atazanavir: a systematic review.
Culley CL; Kiang TK; Gilchrist SE; Ensom MH
Ann Pharmacother; 2013 Apr; 47(4):561-72. PubMed ID: 23548653
[TBL] [Abstract][Full Text] [Related]
12. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan.
Innocenti F; Undevia SD; Iyer L; Chen PX; Das S; Kocherginsky M; Karrison T; Janisch L; Ramírez J; Rudin CM; Vokes EE; Ratain MJ
J Clin Oncol; 2004 Apr; 22(8):1382-8. PubMed ID: 15007088
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetics and irinotecan therapy.
Hahn KK; Wolff JJ; Kolesar JM
Am J Health Syst Pharm; 2006 Nov; 63(22):2211-7. PubMed ID: 17090741
[TBL] [Abstract][Full Text] [Related]
14. Rapid allelic discrimination by TaqMan PCR for the detection of the Gilbert's syndrome marker UGT1A1*28.
Ehmer U; Lankisch TO; Erichsen TJ; Kalthoff S; Freiberg N; Wehmeier M; Manns MP; Strassburg CP
J Mol Diagn; 2008 Nov; 10(6):549-52. PubMed ID: 18832463
[TBL] [Abstract][Full Text] [Related]
15. Nuclear factor κB down-regulates human UDP-glucuronosyltransferase 1A1: a novel mechanism involved in inflammation-associated hyperbilirubinaemia.
Shiu TY; Huang TY; Huang SM; Shih YL; Chu HC; Chang WK; Hsieh TY
Biochem J; 2013 Feb; 449(3):761-70. PubMed ID: 23130636
[TBL] [Abstract][Full Text] [Related]
16. UGT1A1, UGT1A6 and UGT1A7 genetic analysis: repercussion for irinotecan pharmacogenetics in the São Miguel Island Population (Azores, Portugal).
Pacheco PR; Brilhante MJ; Ballart C; Sigalat F; Polena H; Cabral R; Branco CC; Mota-Vieira L
Mol Diagn Ther; 2009; 13(4):261-8. PubMed ID: 19712005
[TBL] [Abstract][Full Text] [Related]
17. Association between the UGT1A1*28 allele and hyperbilirubinemia in HIV-positive patients receiving atazanavir: a meta-analysis.
Du P; Wang A; Ma Y; Li X
Biosci Rep; 2019 May; 39(5):. PubMed ID: 30962262
[No Abstract] [Full Text] [Related]
18. Glucuronidation of acetaminophen is independent of UGT1A1 promotor genotype.
Rauchschwalbe SK; Zühlsdorf MT; Wensing G; Kuhlmann J
Int J Clin Pharmacol Ther; 2004 Feb; 42(2):73-7. PubMed ID: 15180166
[TBL] [Abstract][Full Text] [Related]
19. Genetic polymorphism in the phenobarbital-responsive enhancer module of the UDP-glucuronosyltransferase 1A1 gene and irinotecan toxicity.
Kitagawa C; Ando M; Ando Y; Sekido Y; Wakai K; Imaizumi K; Shimokata K; Hasegawa Y
Pharmacogenet Genomics; 2005 Jan; 15(1):35-41. PubMed ID: 15864124
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia.
Peer CJ; Sissung TM; Kim A; Jain L; Woo S; Gardner ER; Kirkland CT; Troutman SM; English BC; Richardson ED; Federspiel J; Venzon D; Dahut W; Kohn E; Kummar S; Yarchoan R; Giaccone G; Widemann B; Figg WD
Clin Cancer Res; 2012 Apr; 18(7):2099-107. PubMed ID: 22307138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
